证券代码：688114 证券简称：华大智造 公告编号：2025-031 深圳华大智造科技股份有限公司 截至本公告披露日，韦炜先生直接持有公司股份 83,400 股，并通过西藏家 华创业投资合伙企业（有限合伙）间接持有公司股票。离任后，韦炜先生将继续 遵守《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》《上市 公司股东减持股份管理暂行办法》《上海证券交易所科创板股票上市规则》《上 海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减 持股份》等相关规定。 特此公告。 深圳华大智造科技股份有限公司 | | | | | | | | 是否继 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 是否存 | | | | | | | | | | | 续在上 | | | | | | | | 原定任 | | | | | 具体职 | 在未履 | | | | | 离任时 | | | | 离任原 | | 市公司 | | | | 姓名 | 离任职务 | | | | 期 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-031 姓名 离任职务 离任时 间 原定任 期到期 日 离任原 因 是否继 续在上 市公司 及其控 股子公 司任职 具体职 务（如 适用） 是否存 在未履 行完毕 的公开 承诺 韦炜 高级副总 裁、董事会 秘书 2025 年 5 月 21 日 2026 年 9 月 19 日 个人原 因 是 法务 否 一、提前离任的基本情况 韦炜先生自 2020 年担任公司高级副总裁兼董事会秘书以来，勤勉尽责，恪 尽职守，在完善公司治理结构和机制、信息披露、投资者关系管理等方面发挥了 重要作用，公司及董事会对于韦炜先生在任职期间为公司发展所做出的重要贡献 表示衷心感谢和诚挚敬意。 截至本公告披露日，韦炜先生直接持有公司股份 83,400 股，并通过西藏家 华创业投资合伙企业（有限合伙）间接持有公司股票。离任后，韦炜先生将继续 遵守《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》《上市 公司股东减持股份管理暂行办法》《上海证券交易所科创板股票上市规则》《上 海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减 持股份》等相关规定。 ...

Core Insights - A new microbial species named "Niallia tiangongensis" has been discovered in the Chinese space station, marking a significant advancement in understanding microbial diversity in space [1][2][3] Group 1: Discovery and Significance - The discovery of Niallia tiangongensis expands knowledge of microbial diversity in extreme space environments, showcasing China's capabilities in space exploration [1][2] - The research was published in the International Journal of Systematic and Evolutionary Microbiology, highlighting its scientific importance [2] Group 2: Research Methodology - The research utilized the DNBSEQ-T7 sequencing platform developed by BGI Genomics, which is capable of generating at least 7Tb of data in 24 hours, demonstrating advanced technological capabilities [1][2] - Samples were collected by astronauts during the Shenzhou 15 mission in May 2023, using sterile wipes to gather microbial samples from various surfaces within the space station [3] Group 3: Microbial Characteristics - Niallia tiangongensis is a Gram-positive, aerobic, spore-forming rod with a genome size of 5,166,230 base pairs and a G+C content of 35.6 mol% [3][4] - The species exhibits unique traits, including the ability to hydrolyze gelatin, indicating its adaptability to nutrient-limited environments [4] Group 4: Genetic Analysis - Genomic analysis revealed significant differences between Niallia tiangongensis and its closest terrestrial relative, Niallia circulans, with only 83.3% genomic similarity, below the species definition threshold of 95% [3][4] - Key mutations in proteins associated with oxidative stress response and radiation damage repair were identified, enhancing its survival capabilities in space [4]

深圳华大智造科技股份有限公司 2024 年年度股东大会 会议资料 2025 年 6 月 1 | . | . | | | | --- | --- | --- | --- | | | . | | | | | V | | | | | 4 . | | 1 | | 2024 | 年年度股东大会会议须知 3 | | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 5 | | | 2024 | 年年度股东大会会议议案 7 | | | 《关于〈公司 | 2024 年度董事会工作报告〉的议案》 7 | | | 《关于〈公司 | 年度监事会工作报告〉的议案》 8 2024 | | | 《关于〈公司 | 2024 年度财务决算报告〉的议案》 9 | | | 《关于〈公司 | 年度财务预算报告〉的议案》 10 2025 | | | 《关于〈公司 | 2024 年年度报告〉及其摘要的议案》 | 11 | | 《关于公司 2024 | 年度利润分配预案的议案》 12 | | | | 《关于未弥补亏损达实收股本总额三分之一的议案》 13 | | | 《关于续聘公司 | 年度财务报告及内部控制审计机构的议案 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-030 深圳华大智造科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 9 日 15 点 00 分 召开地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议 中心 419 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 9 日 至2025 年 6 月 9 日 不涉及 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | 序号 | | 议案名称 | 投票股东类型 | | --- | --- | --- | --- | ...

Group 1 - Turkish clinical genetic testing laboratory Genoks has announced a partnership with BGI Genomics to enhance its clinical testing capabilities in the local market [1] - The collaboration involves the introduction of BGI's sequencing platform and supporting products [1] - This partnership aims to empower local public health initiatives and advance genomic research in Turkey [1]

Investment Rating - The investment rating for the company is "Accumulate" [7] Core Views - The company is expected to see revenue growth driven by significant increases in installed capacity and ongoing domestic substitution, alongside international expansion opportunities [1][2] - The company achieved a revenue of 3.013 billion yuan in 2024, a year-on-year increase of 3.48%, with a notable revenue of 1.143 billion yuan in Q4, reflecting a 61.64% year-on-year growth [1] - The company anticipates a revenue of 4.488 billion yuan in 2025, with projected growth rates of 15.78%, 18.10%, and 16.75% for the years 2025, 2026, and 2027 respectively [5] Revenue and Profitability - In 2024, the company's gene sequencing business generated revenue of 2.348 billion yuan, a year-on-year increase of 2.47%, with instrument revenue at 960 million yuan (up 6.92%) and reagent revenue at 1.373 billion yuan (up 1.43%) [2] - The company installed nearly 1,270 new units in 2024, marking a historical high and a 49% increase from the previous year [2] - The company reported a net profit of -600.83 million yuan in 2024, with expectations of a gradual return to profitability by 2027 [5][12] Regional Performance - In 2024, revenue from the China region was 1.61 billion yuan, up 11% year-on-year, while the Asia-Pacific region saw a decline of 30% to 230 million yuan [3] - The Americas region achieved revenue of 170 million yuan, reflecting an 8% year-on-year growth, indicating strong performance in certain markets despite challenges in others [3] Research and Development - The company maintained high R&D investment of 746 million yuan in 2024, representing 24.8% of revenue, aimed at enhancing product competitiveness [4] - The company is focusing on new product launches, including the portable low-throughput sequencer E25 and the desktop mid-throughput sequencer G99, which are expected to drive market share growth [4] Future Outlook - The company forecasts revenues of 3.488 billion yuan in 2025, with a net profit of -272 million yuan, indicating a path towards recovery and growth [5][12] - The ongoing development of spatial sequencing and single-molecule sequencing technologies is expected to open new market opportunities [4]

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

Core Viewpoint - The IVD industry is experiencing a significant downturn in revenue and profits, with over 70% of companies reporting a year-on-year decline in revenue and more than half facing losses or drastically reduced profits [2][5]. Revenue and Profit Trends - In Q1 2025, major IVD companies such as Mindray Medical, Dian Diagnostics, and RunDa Medical reported substantial declines in both revenue and net profit, with Mindray's revenue at 8.237 billion yuan (down 12.12%) and net profit at 2.629 billion yuan (down 16.81%) [2][4]. - Among 60 IVD companies analyzed, 16 reported revenue growth, with 8 achieving both revenue and net profit growth [2]. Market Challenges - The IVD sector is facing multiple challenges, including a slowdown in the conventional medical testing market, stricter cost control policies in healthcare, and the impact of centralized procurement policies [5][6]. - The anticipated centralized procurement in 28 provinces is expected to further pressure IVD companies, particularly in the high-volume chemical luminescence market [6]. Company Strategies and Innovations - Some companies are adapting by focusing on niche markets and innovative product offerings, such as New Industry and Sansure Bio, which reported revenue growth of 10.12% and 21.62% respectively in Q1 2025 [9]. - Companies are also exploring international markets, with Mindray's overseas revenue reaching 16.43 billion yuan in 2024, accounting for 44.75% of total revenue [9][10]. Technological Advancements - The IVD industry is witnessing a shift towards digitalization and AI integration, with partnerships like that of BGI and Dian Diagnostics aiming to enhance diagnostic efficiency and precision [10][11]. - The emergence of AI technologies is reshaping the IVD landscape, although challenges remain in data integration and commercialization [11].

Investment Rating - The report maintains an "Accumulate" rating for the company, indicating an expected relative performance increase of 5% to 15% over the next 6 to 12 months compared to the benchmark index [2][9]. Core Views - The company has shown resilience in performance amidst geopolitical risks, with steady growth in global sequencing installations. The core sequencing business is experiencing robust growth, supported by domestic market recovery and accelerated overseas expansion [2][6]. - The company achieved a revenue of 3.01 billion yuan in 2024, reflecting a year-on-year growth of 3.48%. However, the net profit attributable to the parent company was -601 million yuan, a slight improvement of 1.10% year-on-year [3][6]. - The report highlights the company's competitive advantage as a domestic leader in sequencing instruments, with a global market share of approximately 7.1% based on revenue and 28.2% based on new installations [6]. Summary by Sections Financial Performance - The company forecasts revenues of 3.61 billion yuan for 2025, with a growth rate of 20%. The net profit is expected to improve significantly, reaching -177 million yuan, a 70% year-on-year increase [2][7]. - In Q1 2025, the company reported a revenue of 455 million yuan, a decline of 14.26% year-on-year, while the net profit attributable to the parent company was -133 million yuan, an increase of 33.67% year-on-year [3][6]. Market Position - The company has accelerated its global expansion, with nearly 900 overseas marketing personnel and a significant increase in installed sequencing machines, totaling over 4,500 units globally by the end of 2024 [6]. - The domestic market share for newly installed instruments reached approximately 63.8%, with revenue market share increasing to 39% [6]. Cost and Efficiency - The report notes a decrease in sales expense ratio to 25.42% and a slight increase in management expense ratio to 19.98%. The R&D expense ratio decreased to 24.77%, indicating improved operational efficiency [6]. - The gross margin for 2024 was reported at 55.51%, a decrease of 3.96 percentage points year-on-year, primarily due to changes in product mix [6]. Future Outlook - The company is expected to continue benefiting from innovative products and global channel development, with projected revenues of 4.5 billion yuan in 2026 and 5.6 billion yuan in 2027, reflecting a growth rate of 25% and 24% respectively [2][6]. - The net profit is anticipated to turn positive by 2026, reaching 182 million yuan by 2027, indicating a significant turnaround from previous losses [2][6].